Amid the expected approval of the company's novel osteoarthritis therapy, investors showed a strong appetite for Biosolution Co. Ltd.'s initial public offering on Aug. 9-10, helping the South Korean cell therapy venture to raise KRW43.5bn ($38.5m).
The company priced 1.5 million common shares at KRW29,000 each in the IPO, which was at the top end of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?